Tiziana Life Sciences (TLSA) Prices 11M ADS Follow-Offering at $5.20/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pre-Open Stock Movers 07/31: (PINS) (FB) (AAPL) (AMZN) Higher; (TEAM) (MOH) (RDFN) Lower (more...)
July 31, 2020 9:23 AM EDTPre-Open Stock Movers
electroCore, Inc. (Nasdaq: ECOR) 81.8% HIGHER; announced more information about availability, distribution and pricing for gammaCore Sapphire CV non-invasive vagus nerve stimulation (nVNS) therapy under its Emergency Use Authorization (EUA). The EUA allows for the use of gammaCore Sapphire CV at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief.
Tiziana Life Sciences plc... More
Tiziana Life Sciences (TLSA) Announces Submission of Patent Application for Nasal Administration of Foralumab for Treatment of COVID-19 Patients
July 31, 2020 6:24 AM EDTTiziana Life Sciences plc (Nasdaq: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), for the treatment of COVID-19 either alone or in combination with other anti-viral drugs. Recent clinical studies imply that a combination of anti-inflammatory and anti-viral drugs may be more effective to treat patients at different stages of COVID-19 disease.
Nasal administration with Foralumab could potentially... More
